AMD

David Hutton of Ophthalmology Times talks with Adrienne Scott, MD, FASRS, about her part in a panel discussion detailing emerging therapies for AMD.

According to the company, ABBV-RGX-314 continues to be well tolerated in over 100 patients from three dose levels with no drug-related serious adverse events. The new data was presented at the Hawaiian Eye and Retina meeting in Maui, by John Pitcher, MD, and includes 6-month results from two additional dose level 3 cohorts.

A new case-control study found that older people ages 70 and older living in South Korea’s urban areas were at a significantly higher risk for developing incident exudative age-related macular degeneration.

Principle findings showed that aflibercept 8 mg demonstrated similar improvements in BCVA and CST when compared to the 2 mg dose of aflibercept.

The data indicated that patients with Alzheimer’s disease who were treated with acetylcholinesterase inhibitors had a slightly lower hazard of developing AMD compared with untreated patients.

The European Union approval applies to aflibercept 8 mg for treatment of nAMD and DME.

In a letter to shareholders, Ricciardi provided updates on Cognition’s 2024 pipeline and expected advances for several diseases.

The company announced more advancements of its RASP modulator platform, including plans for ADX-629 and ADX-246.

If granted, this device would be assigned an official classification as a Class II device with special controls.

This study compared AVT06 with aflibercept (Eylea) in patients with neovascular AMD.

According to a news release, the services will be provided for RetinalGeniX Technologies’ Institutional Review Board to conduct a study to personalize medical evaluations for patients receiving treatment for wet macular degeneration.

According to the company, the designation follows interim Phase 1 PRISM clinical data for 4D-150 that demonstrated an encouraging safety, tolerability and clinical activity profile in patients with wet age-related macular degeneration.

The suspension is unrelated to product quality and will lift in February of 2024.

Randomization has been completed and, according to the company, topline data is expected during the third quarter of 2024.

The research marks the first attempt at integrating a photoactivatable anti-angiogenic agent with a photosensitizer into a single nanoformulation for AMD treatment.

Umedaptanib pegol has potential to improve outcomes if used as a first-line medication prior to patients receiving treatments targeting VEGF.

According to the company, OCU410 is a modifier gene therapy product candidate being developed for dry AMD.

The study saw encouraging results and helped to identify suitable dosing levels for future clinical trials.

Both oxidative stress and HIF-1 have been previously implicated in the development of AMD, but this research more clearly shows how cells are affected.

The predictive factors were the previous number of anti-vascular endothelial growth factor and the photometry laser flare-cell (LFCP) value.

A retrospective observational study shows BCVA was maintained after 6 months for patients with neovascular AMD.

The company announced key secondary endpoints were achieved with both EYP-1901 doses. These include a more than 80% reduction in treatment burden, with nearly two-thirds of eyes supplement-free up to 6 months.

The investigators wanted to determine if subclinical changes in the blood–aqueous barrier and the retinal physiology developed after anti-VEGF treatments with aflibercept, brolucizumab, and or faricimab .

The ranibizumab biosimilar is a recombinant antigen-binding fragment (Fab).